Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

30-37. (canceled)

- 38. (previously presented) A method of effectively treating pain in humans or other mammals, comprising administering to a patient an analgesic combination consisting essentially of nimesulide and/or at least one pharmaceutically acceptable salt thereof; and oxycodone and/or at least one pharmaceutically acceptable salt thereof such that the dosing interval of the nimesulide and/or at least one pharmaceutically acceptable salt thereof overlaps with the dosing interval of the oxycodone and/or at least one pharmaceutically acceptable salt thereof.
- 39. (previously presented) The method of claim 38, wherein the nimesulide and/or at least one pharmaceutically acceptable salt thereof and the oxycodone and/or at least one pharmaceutically acceptable salt thereof are administered orally.
- 40. (previously presented) The method of claim 38, wherein the nimesulide and/or at least one pharmaceutically acceptable salt thereof and the oxycodone and/or at least one pharmaceutically acceptable salt thereof are administered in a single oral dosage form.
- 41. (previously presented) The method of claim 38, wherein the oxycodone and/or at least onepharmaceutically acceptable salt thereof would be sub-therapeutic if administered without the nimesulide and/or at least one pharmaceutically acceptable salt thereof.
- 42. (previously presented) The method of claim 38, wherein the nimesulide and/or at least one pharmaceutically acceptable salt thereof, is administered before, simultaneously with, or after administration of the oxycodone and/or at least one

pharmaceutically acceptable salt thereof, such that the dosing interval of the nimesulide and/or at least one pharmaceutically acceptable salt thereof overlaps with the dosing interval of the oxycodone and/or at least one pharmaceutically acceptable salt thereof.

- 43. (previously presented) A method of reducing the oxycodone and/or at least one pharmaceutically acceptable salt thereof required to treat a patient affected with pain, comprising co-administering said oxycodone and/or at least one pharmaceutically acceptable salt thereof with nimesulide and/or at least one pharmaceutically acceptable salt thereof, to augment the analgesia attributable to said oxycodone and/or at least one pharmaceutically acceptable salt thereof during at least a portion of the dosage interval of said oxycodone and/or at least one pharmaceutically acceptable salt thereof.
- 44. (previously presented) A method of reducing the amount of nimesulide and or at least one pharmaceutically acceptable salt thereof required to treat a patient affected with pain comprising co-administering said nimesulide and/or at least one pharmaceutically acceptable salt thereof with an effective amount of oxycodone and/or at least one pharmaceutically acceptable salt thereof, to augment the analgesia attributable to said nimesulide and/or at least one pharmaceutically acceptable salt thereof during at least a portion of the dosage interval of said nimesulide and/or at least one pharmaceutically acceptable salt thereof.
- 45. (canceled)

. ت

- 46. (previously presented) The method of claim 38, wherein the oxycodone and/or at least one pharmaceutically acceptable salt thereof is present in an amount from about 2.5 mg to about 800 mg.
- 47. (previously presented) The method of claim 38, wherein the ratio of oxycodone and/or at least one pharmaceutically acceptable salt thereof to nimesulide and/or at least one pharmaceutically acceptable salt thereof is from about 0.0001:1 to about 1:1.